Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2024-12-16 Share Issue/Capital Cha…
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - IRX 4 pages 14.8KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation (expiry) of certain securities (options) for Inhalerx Limited. It includes specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is a formal announcement related to changes in the company's issued securities, specifically the cessation of certain options. This type of document corresponds to announcements about changes in capital structure or securities status. Given the content and the nature of the announcement, it fits best under the category 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes including cessation of securities. The document length is 4204 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Therefore, the classification is SHA with high confidence.
2024-12-16 English
Application for quotation of securities - IRX 6 pages 18.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue dates, and related information about the securities issued. It references a previous Appendix 3B announcement about the proposed issue of securities. The document is not a financial report, earnings release, or management discussion, but rather a formal announcement related to capital market activities, specifically the quotation of new securities. This fits the category of Share Issue/Capital Change announcements, as it concerns the issuance and quotation of new shares and options.
2024-12-16 English
Change of Director's Interest Notice - Sean Williams 2 pages 307.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a change in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change, and the value/consideration. This is a clear report of a personal share transaction by a company director. The document length is 4129 characters, which is consistent with a detailed director's dealing notice. There is no indication that this is an annual report, earnings release, or any other type of report. Therefore, the document fits the definition of Director's Dealing (DIRS).
2024-12-16 English
Change of Director's Interest Notice - James Barrie 2 pages 283.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares acquired, the nature of the interest, and the consideration paid. The document is short (3459 characters) and focuses solely on insider share transactions by a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). There is no indication that this is a full financial report or an announcement of a report, nor does it fit other categories such as management changes or regulatory filings. Therefore, the correct classification is DIRS.
2024-12-16 English
Cleansing Notice 1 page 176.7KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice from InhaleRx Ltd regarding the issuance of ordinary shares, referencing compliance with sections of the Corporations Act related to disclosure exemptions. It mentions the issuance of shares without disclosure under Part 6D.2 and provides a cleansing notice as required by law. The document does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about a share issuance event and compliance with disclosure requirements, not a full financial report or earnings release. The document length is short (2376 characters) and it serves as a formal notification to the market about the share issuance and related legal compliance. This fits the category of Share Issue/Capital Change (SHA).
2024-12-16 English
Issue of Securities Following General Meeting Approval 1
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the issuance of securities following shareholder approval at a recent General Meeting. It mentions that ASX announcements will be separately lodged and does not contain any financial statements, detailed financial data, or comprehensive report content. The document length is only 1803 characters, which is quite brief and fits the pattern of a regulatory announcement rather than a full report. It is not a report itself but an announcement of a corporate action (securities issuance) following shareholder approval. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to issuance of securities and capital structure changes.
2024-12-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.